Compare GCO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | CLLS |
|---|---|---|
| Founded | 1924 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 299.0M |
| IPO Year | N/A | 2007 |
| Metric | GCO | CLLS |
|---|---|---|
| Price | $23.89 | $5.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $31.33 | $8.00 |
| AVG Volume (30 Days) | ★ 171.4K | 133.5K |
| Earning Date | 12-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $2,382,104,000.00 | $82,551,000.00 |
| Revenue This Year | $4.60 | $32.58 |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | $6,453.36 | ★ N/A |
| Revenue Growth | 2.76 | ★ 129.04 |
| 52 Week Low | $16.19 | $1.10 |
| 52 Week High | $44.80 | $5.48 |
| Indicator | GCO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 66.42 |
| Support Level | $22.63 | $4.47 |
| Resistance Level | $24.38 | $4.90 |
| Average True Range (ATR) | 1.80 | 0.28 |
| MACD | -1.22 | 0.00 |
| Stochastic Oscillator | 13.18 | 81.63 |
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.